Gilead Sciences (GILD) Tops Q3 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences Announces Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion
Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion
Oncology Sales Increased 79% Year-Over-Year to $578 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.
Chairman and Chief Executive Officer of Gilead Sciences, Daniel ODay said: This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy... More
